BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
https://www.nejm.org/doi/full/10.1056/NEJMoa2101765?query=featured_home
METHOD
Vaccinations, December 20, 2020, to February 1, 2021
Matched to unvaccinated controls in a 1:1 ratio
According to demographic and clinical characteristics
N = 596,618 (in each group)
DOCUMENTED INFECTIONS, 10,561
Symptomatic infections, 5,996 (57%)
Requiring hospitalisation, 369
Severe cases of Covid-19, 229
Deaths, 41
RESULTS
Vaccine effectiveness at days 14 through 20 after the first dose
Vaccine effectiveness at 7 or more days after the second dose
Documented infection
46% and 92%
Symptomatic Covid-19
57% and 94%
Hospitalization
74% and 87%
Last hospitalisation in the vaccinated group at 32 days
Severe disease
62% and 92%
Last severe case in the vaccinated group at 30 days
Effectiveness in preventing death
72% for days 14 through 20 after the first dose
Deaths after 44 days
Vaccinated group, 9
Unvaccinated group, 32
Last death in the vaccinated group at 30 days
CONCLUSIONS
Consistent with a gradual daily increase in vaccine effectiveness
This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Source